To help treat the effects of Covid-19, President Donald Trump has reportedly received dexamethasone. Deck-of-who-the-phone? Dexys Midnight Runners hold the phone? No, dexamethasone. It is a ...

One of the physicians treating President Donald Trump, Dr. Brian Garibaldi, said Sunday the President is being given the steroid drug dexamethasone as part of his Covid-19 treatment. It’s an ...

Dexamethasone oral tablet is a generic drug that’s prescribed for many conditions, including allergic reactions and inflammation. Dexamethasone belongs to a class of drugs called corticosteroids (also ...

Herpes simplex virus (HSV) encephalitis, caused by HSV types 1 and 2, is the most common sporadic viral encephalitis worldwide, with an annual incidence of around 2·2–4·6 per million people.1 Before ...

Dexamethasone became the latest drug to get attention for its potential in treating COVID, when a study declared this week there were promising results in trials with the drug. But what exactly is ...

Treatment with the antiviral remdesivir (Veklury) plus dexamethasone was linked to fewer deaths among patients hospitalized for COVID-19 compared with dexamethasone monotherapy, a retrospective study ...

Dexamethasone treatment failed to demonstrate noninferiority to surgery for chronic subdural hematoma and was associated with more complications and a greater risk of later surgery, according to ...

The race for an effective treatment for Covid-19 has been littered with false starts and uncertain outcomes. To date, no treatment improves the odds of Covid-19 patients surviving. However, one ...

The president’s physician says President Trump was treated with a steroid after a drop in oxygen levels on Saturday. Dr. Sean Conley said at a news conference on Sunday that he was given the steroid ...

Please provide your email address to receive an email when new articles are posted on . Oral dexamethasone reduced length of stay and ICU admissions in adults with community-acquired pneumonia, ...

Santen EMEA and NTC are delighted to announce that the results of their phase III clinical study, LEADER7, have been published in Eye. The study demonstrated for the ...